Clinical trials: Antiphospholipid Syndrome
Antiphospholipid (aPL)-Positive
Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
The primary purpose of this study was to evaluate the safety and tolerability of intravenous (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of the following non-criteria manifestations of…
- Trial name
- NCT02128269
- Testing
- Study Drug- ALXN1007
- Where
- 9 sites in United States, Brazil and 4 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Antiphospholipid Syndrome
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
RITuximab AntiphosPholipid Syndrome (RITAPS) Study is designed to evaluate whether a medication called rituximab would reduce the signs and symptoms of antiphospholipid antibody (aPL) -related certain clinical problems.
- Trial name
- RITAPS (NCT00537290)
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid Syndrome
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and safe in reducing the risk of cardiovascular disease and blood clots in patients with antiphospholipid antibodies or Antiphospholipid…
- Trial name
- NCT00674297
- Testing
- Fluvastatin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Hospital for Special Surgery, New York
Antiphospholipid Syndrome in Pregnancy, Pregnancy Loss
AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study
The APPLE pilot trial is a feasibility study that is a multicentre, open-label, randomized controlled trial. Pregnant women with antiphospholipid syndrome (APS) and a history of late (≥10 weeks gestation) or recurrent early (2…
- Trial name
- APPLE (NCT03100123)
- Testing
- Aspirin 81 mg, Low-molecular-weight heparin
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Ottawa Hospital Research Institute
Antiphospholipid Antibody Syndrome, End Stage Renal Disease
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Catastrophic Antiphospholipid Antibody Syndrome (CAPS) is a rare condition in which life-threatening blood clots form in multiple organs simultaneously and can lead to multi-organ system failure and death.
- Trial name
- NCT01029587
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Recurrent Abortion
Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome
The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with…
- Trial name
- NCT01051778
- Testing
- enoxaparin 40mg plus low dose aspirin, Heparin calcium5,000 U twice daily plus low dose aspirin
- Where
- 2 sites in Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Antiphospholipid Syndrome
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
- Trial name
- NCT01784523
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hospital for Special Surgery, New York